Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (321-330 of 442) with videos related to

Pageof 45
Sort By:
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Pageof 45

Showing results (321-330 of 442) with videos related to

Sort By:
Pageof 45
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid TumorsGerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
Experimental Hematology & Oncology|December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumorsKyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Pageof 45